Jazz Pharmaceuticals PLC (JAZZ)
Pretax margin
| Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | Dec 31, 2019 | ||
|---|---|---|---|---|---|---|
| Earnings before tax but after interest (EBT) | US$ in thousands | 294,932 | -382,705 | -113,552 | 272,133 | 450,213 |
| Revenue | US$ in thousands | 3,809,840 | 3,569,430 | 2,999,690 | 2,284,420 | 2,097,480 |
| Pretax margin | 7.74% | -10.72% | -3.79% | 11.91% | 21.46% |
December 31, 2023 calculation
Pretax margin = EBT ÷ Revenue
= $294,932K ÷ $3,809,840K
= 7.74%
The pretax margin of Jazz Pharmaceuticals plc has fluctuated in recent years. In 2019, the company recorded a relatively high pretax margin of 20.83%, indicating strong profitability before taxes. However, this margin decreased significantly in 2020 to 11.51%, although it remained positive.
In 2021, the pretax margin further declined to -3.67%, indicating that the company experienced a loss before tax during that period. This negative performance improved in 2022, but the pretax margin remained negative at -10.46%, suggesting ongoing challenges in profitability.
By the end of 2023, Jazz Pharmaceuticals plc managed to increase its pretax margin to 7.69%, showing a positive turnaround from the previous year. It is essential for the company to continue monitoring and improving its operational efficiency and cost management to sustain and increase profitability levels in the future.
Peer comparison
Dec 31, 2023